Scottish Enterprise is Scotland's primary economic development agency, operating as a non-departmental public body of the Scottish Government. Its mission is to foster economic growth by supporting the development of innovative, high-wage industries with a strong international presence. The organization plays a crucial role in assisting small and medium-sized enterprises (SMEs) in securing financing, helping them engage with funders and access the necessary capital for expansion. Scottish Enterprise invests through its arm, the Scottish Investment Bank, which focuses on various sectors, including renewable energy, life sciences, and creative industries. The firm engages in both direct and fund-of-fund investing, typically providing financial support in the form of equity or loans ranging from £0.01 million to £10 million. Additionally, it collaborates with public and private sectors and works alongside UK and international investors to enhance the funding landscape for Scottish businesses. Through these initiatives, Scottish Enterprise aims to create a sustainable economic impact and strengthen the funding market within Scotland.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Cytomos Limited, based in Edinburgh, United Kingdom, specializes in developing advanced technologies for cell sorting and analysis in laboratory research and clinical diagnostics. Established in 2011, the company focuses on its patented Dielectric Spectroscopy (CDS™) technology, which allows for unbiased, label-free analysis of individual cells with single-cell resolution. This technology is particularly valuable in the biopharma and cell therapy sectors, as it enables automated and quantitative assessment of samples, aiding in phenotypic drug discovery and stem cell therapy. By leveraging proprietary machine learning algorithms, Cytomos provides deep insights into bioprocesses, enhancing the efficiency of cell-based diagnostics and enabling researchers to make informed decisions regarding dosage and treatment protocols.
BioCaptiva
Seed Round in 2022
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
Aiber specializes in developing innovative software solutions for in-flight medical care within the aviation industry. The company's flagship product, MIME Pro, provides essential first aid emergency care guidance to cabin crew during medical incidents on flights. This software utilizes Bluetooth sensors to monitor vital signs in real time, allowing for the identification and communication of patient conditions, including deterioration and improvement. Founded in 2015 and headquartered in Inverness, United Kingdom, Aiber is dedicated to enhancing emergency response capabilities in aviation through its advanced technology.
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
Invizius Ltd. is a medical technology company based in Edinburgh, United Kingdom, founded in 2018. The company specializes in developing H-Guard technology, which aims to mitigate the side effects associated with hemodialysis treatments. By addressing these side effects, Invizius seeks to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis.
Altair Medical is developing real-time monitoring solutions to allow patients with respiratory conditions and their doctors to track their respiratory rates and performance out of hospital, at home and at work. Combining proprietary sensor technology and an innovative AI driven digital therapeutic software platform, Altair’s technology enables doctors to rationalise medication use, identify early signs of deterioration, reduce or shorten hospital admissions and reduce face to face appointments.
BioCaptiva
Seed Round in 2021
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
ClinSpec Dx™ are pioneering a new spectroscopic method for blood serum analysis, allowing same-day detection and grading of a range of diseases, with first applications to brain cancer.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
Manus Neurodynamica Ltd manufactures medical diagnostic technologies for neuromotor impairments, including the non-invasive diagnosis and monitoring of Parkinson’s disease. Its technologies are used in academic research, pharmaceutical research, and non-medical applications. The company was founded in 2008 and is based in North Shields, United Kingdom.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Aiber specializes in developing innovative software solutions for in-flight medical care within the aviation industry. The company's flagship product, MIME Pro, provides essential first aid emergency care guidance to cabin crew during medical incidents on flights. This software utilizes Bluetooth sensors to monitor vital signs in real time, allowing for the identification and communication of patient conditions, including deterioration and improvement. Founded in 2015 and headquartered in Inverness, United Kingdom, Aiber is dedicated to enhancing emergency response capabilities in aviation through its advanced technology.
Aiber specializes in developing innovative software solutions for in-flight medical care within the aviation industry. The company's flagship product, MIME Pro, provides essential first aid emergency care guidance to cabin crew during medical incidents on flights. This software utilizes Bluetooth sensors to monitor vital signs in real time, allowing for the identification and communication of patient conditions, including deterioration and improvement. Founded in 2015 and headquartered in Inverness, United Kingdom, Aiber is dedicated to enhancing emergency response capabilities in aviation through its advanced technology.
Invizius Ltd. is a medical technology company based in Edinburgh, United Kingdom, founded in 2018. The company specializes in developing H-Guard technology, which aims to mitigate the side effects associated with hemodialysis treatments. By addressing these side effects, Invizius seeks to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis.
MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients with autoimmune diseases and cancers. Established in 2009, the company is known for its lead product, annexuzlimab, a monoclonal antibody designed to address various autoimmune conditions. MedAnnex aims to create first-in-class antibody therapies that significantly enhance the quality of life for individuals affected by these serious health issues. Through its research and development efforts, the company is committed to advancing therapeutic options in the biotechnology sector.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
Invizius Ltd. is a medical technology company based in Edinburgh, United Kingdom, founded in 2018. The company specializes in developing H-Guard technology, which aims to mitigate the side effects associated with hemodialysis treatments. By addressing these side effects, Invizius seeks to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
MOFgen Ltd is an award winning VC-backed SME spin-out from the University of St Andrews and is the first company to commercialise MOFs for medical and therapeutic applications. The company’s patented technology was pioneered in the laboratories of world renowned porous material scientist Prof Russell Morris FRS within the School of Chemistry at St Andrews. With roots in the leading research group of its field, MOFgen is exploiting its strong IP and knowhow assets in the areas of MOF design, application, manufacturing and formulation to deliver cutting edge solutions to healthcare challenges. Through an ethos of innovation and collaboration, MOFgen works closely with its partners, to develop bespoke solutions to prevent healthcare associated infections, avoid bacterial resistance, heal chronic wounds and address arterial access.
Mironid Limited is a drug discovery company focused on developing therapeutic candidates aimed at treating degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014 and based in Newhouse, United Kingdom, Mironid employs a unique Physiology Mirroring Approach to design assays that replicate the drug target's conformation and environment found in living cells. The company's pipeline features Novel ShoLo compounds for chronic inflammatory diseases and Novel LoAc compounds for degenerative kidney diseases. By modulating the activity of key cell signaling proteins, Mironid aims to create high-value therapeutics that address significant unmet medical needs, thereby enhancing the health and quality of life for patients.
Clear Surgical Ltd designs, manufacture, and sell medical devices for use in surgery. Its products include The Oplight provides open cavity surgery and retraction for surgical incision while using LED (Light-emitting diode) technology to illuminate the part of the body being operated upon and its Cannulated Reduction Forceps product combines orthopedic reduction forceps with a guidance system that provides operating ports at either side of the forceps and guides for optimum implant placement. The company was founded in 2013 and is based in Larbert, United Kingdom.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Clear Surgical Ltd designs, manufacture, and sell medical devices for use in surgery. Its products include The Oplight provides open cavity surgery and retraction for surgical incision while using LED (Light-emitting diode) technology to illuminate the part of the body being operated upon and its Cannulated Reduction Forceps product combines orthopedic reduction forceps with a guidance system that provides operating ports at either side of the forceps and guides for optimum implant placement. The company was founded in 2013 and is based in Larbert, United Kingdom.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Bedi OralCare Limited, based in Edinburgh, United Kingdom, specializes in manufacturing dental products tailored for young children, individuals with disabilities, and dementia sufferers. Established in 2013, the company aims to enhance oral health accessibility for all. Its flagship product, Dental Shield, assists health professionals in examining patients by facilitating mouth opening for routine dental procedures. Another significant offering, the Bedi Tray, allows for dental impressions in preschool children without the need for restraint, promoting a more comfortable experience. The company is committed to improving the quality of life and overall well-being of its patients through its innovative dental care solutions.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.
Bedi OralCare Limited, based in Edinburgh, United Kingdom, specializes in manufacturing dental products tailored for young children, individuals with disabilities, and dementia sufferers. Established in 2013, the company aims to enhance oral health accessibility for all. Its flagship product, Dental Shield, assists health professionals in examining patients by facilitating mouth opening for routine dental procedures. Another significant offering, the Bedi Tray, allows for dental impressions in preschool children without the need for restraint, promoting a more comfortable experience. The company is committed to improving the quality of life and overall well-being of its patients through its innovative dental care solutions.
Clear Surgical Ltd designs, manufacture, and sell medical devices for use in surgery. Its products include The Oplight provides open cavity surgery and retraction for surgical incision while using LED (Light-emitting diode) technology to illuminate the part of the body being operated upon and its Cannulated Reduction Forceps product combines orthopedic reduction forceps with a guidance system that provides operating ports at either side of the forceps and guides for optimum implant placement. The company was founded in 2013 and is based in Larbert, United Kingdom.
Dysis Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in the design, development, manufacture, and marketing of imaging systems for the non-invasive detection of cancerous and pre-cancerous lesions. The company's flagship product, the DYSIS Colposcope, utilizes patented optical and software techniques to scan the cervix, measure the aceto-whitening reaction, and present findings in an intuitive color-coded map. This technology aids medical practitioners in the early detection, diagnosis, and monitoring of cervical neoplasia, as well as in identifying biopsy sites. In addition to the colposcope, Dysis Medical offers various accessories, including disposable and reusable specula, diathermy loops, and coagulation balls, along with software for data management and image analysis. Founded in 2002 and previously known as FORTH Photonics Limited until its rebranding in 2011, Dysis Medical also operates sales offices in Tampa, Florida, and Athens, Greece.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby improving efficiency and productivity in healthcare settings. The company's key offerings include the Blackford Workflow Server, which integrates seamlessly into hospital IT systems to facilitate image pre-processing, and the Blackford Smart Localizer, designed for easy comparison of multiple imaging studies within the Philips IntelliSpace PACS interface. Furthermore, Blackford Custom Solutions provides libraries that support the Workflow Server, while the company also develops tailored image processing capabilities for various clients, including radiologists and healthcare enterprises. Founded in 2010 as a spin-out from the University of Edinburgh, Blackford Analysis has established partnerships with leading imaging system providers and has expanded its presence with sales offices in the UK and the USA. Through its innovative products, the company aims to save clinicians time and enhance communication across healthcare enterprises.
Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby improving efficiency and productivity in healthcare settings. The company's key offerings include the Blackford Workflow Server, which integrates seamlessly into hospital IT systems to facilitate image pre-processing, and the Blackford Smart Localizer, designed for easy comparison of multiple imaging studies within the Philips IntelliSpace PACS interface. Furthermore, Blackford Custom Solutions provides libraries that support the Workflow Server, while the company also develops tailored image processing capabilities for various clients, including radiologists and healthcare enterprises. Founded in 2010 as a spin-out from the University of Edinburgh, Blackford Analysis has established partnerships with leading imaging system providers and has expanded its presence with sales offices in the UK and the USA. Through its innovative products, the company aims to save clinicians time and enhance communication across healthcare enterprises.
Ambicare Health Ltd specializes in the development of wearable light sources for both medical and consumer healthcare applications. The company’s flagship product, Ambulight PDT, is a light-emitting sticking plaster designed for the treatment of non-melanoma skin cancer, utilizing photodynamic therapy as a non-surgical alternative. In addition to this, Ambicare offers the Lustre Pure Light Classic and Lustre Pure Light Pro, both of which provide blue light therapy aimed at combating spots and acne. These products are designed to replicate clinically proven light therapies in a more accessible format for use in home settings. Founded in 2004 through collaborative research at the University of St. Andrews and Tayside Health Board, Ambicare has focused on creating convenient, LED-based devices that address various dermatological conditions. The company markets its products through distributors and online platforms from its base in Livingston, United Kingdom.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
B1 Medical
Venture Round in 2006
B1 Medical develops and manufactures medical devices for orthopedics. B1 Medical develops and markets products such as soft tissue monitoring, fracture fixation and small joint prothesis products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.